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Abstract Tumor necrosis factor-a inhibited growth of cultured 
MCF-7 human breast cancer cells in a dose dependent manner. 
Tumor necrosis factor-a also markedly increased glucose 
consumption, and its cytotoxicity was modified by glucose 
concentrations in the growth medium; higher glucose levels were 
associated with increased cell survival. However, when the cells 
were perfused in physiological conditions, very high levels of 
tumor necrosis factor-a (200 ng/ml) in the perfusion solution had 
no inhibitory effects. Moreover, tumor necrosis factor-a had no 
effects on 3 1 P nuclear magnetic resonance spectra of the perfused 
cells. In the traditional growth inhibition assays, cells are 
incubated for several days with a drug, a situation where their 
metabolism is altered due to the depletion of nutrients, the 
accumulation of toxic waste materials and pH changes. 
Perfusion experiments are more relevant to in vivo conditions, 
and may be used for studying metabolic processes and the 
mechanisms of action of therapeutic agents. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Tumor necrosis factor-a (TNF-a ) is a polypeptide which 
has an extensive array of biological activities, and its effects 
are initiated by its binding to specific cell surface receptors 
[1,2]. T N F - a inhibits the growth of some, but not all, tumor 
cell lines, while sparing normal cells [3,4]. However, this se-
lective inhibition is due to different signals generated by the 
cytokine, rather than the number of T N F - a receptors [3,5]. 
The cell-specific post-receptor mechanism of action of T N F - a 
is still ill-defined. It involves diverse and complex metabolic 
alterations, and metabolic inhibitors, such as cycloheximide 
and actinomycin D, enhance the T N F - a induced cytotoxicity 
[6,7]. 
N M R spectroscopy is a very valuable method for studying 
the metabolism of intact cells and tissues in a continuous non-
invasive manner [8,9]. We used 3 1P N M R to assess the effects 
of T N F - a on perfused MCF-7 human breast cancer cells in 
physiological conditions. Cytotoxicity and glucose consump-
tion were also evaluated in cultured cells treated with T N F - a . 
Our data point to the pitfalls in the interpretations of results 
obtained in in vitro experiments. 
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2. Materials and methods 
2.1. Cells and materials 
MCF-7 human breast cancer cells from the National Institutes of 
Health [10] were grown in IMEM (11 mM glucose), supplemented 
with penicillin-streptomycin-nystatin, L-glutamine and 5% fetal calf 
serum, under 5% CO2 environment. IMEM and supplements were 
purchased from Gibco (Grand Island, NY, USA). Chemicals were 
purchased from Sigma Chemicals (St. Louis, MO, USA) unless oth-
erwise indicated, and were of the highest available purity. Recombi-
nant TNF-a was from Genzyme Co. (Cambridge, MA, USA). 
2.2. Cell survival and glucose consumption assays 
The effects of TNF-a on MCF-7 cells were studied in cell survival 
assays. 25 X 104 cells were plated in 25-cm2 flasks in 10 ml of IMEM 
(11 mM glucose). Twenty-four hours later, the medium was replaced 
with new growth medium containing 4, 11 or 25 mM glucose with 
various concentrations of TNF-a. Cells were harvested after 2 or 
5 days, and the surviving cells were counted (Coulter counter, Coulter 
Electronics, Hialeah, FL, USA). For glucose consumption assays, the 
cells were similarly plated, and when they reached 40 ± 5% conftuency, 
the medium was changed to IMEM (11 mM glucose) with various 
TNF-a concentrations. After 2 days, samples of medium were taken 
for glucose measurements, and a cell count (in flasks plated only 
for this purpose) was performed. Twenty-four hours later, medium 
samples were withdrawn again, and all cells were harvested and 
counted. 
2.3. Perfusion of cells and NMR spectroscopy 
The essentials of cellular perfusion are that metabolic events are 
unhampered; thus, substrates and nutrients can be continuously fur-
nished, and waste products removed, while stable pH levels and a 
temperature of 37°C are maintained. In the present studies we used 
the method of cellular embedding in sodium alginate micro-capsules 
[11], prepared in sterile conditions in a biological hood. MCF-7 cells 
were grown to 80-90% conftuency (six experiments), harvested with 
0.25% trypsin-0.05% EDTA, centrifuged at 4°C at 750 Xg for 7 min, 
and washed twice with medium. 1.5-2X108 cells were used in each 
experiment, and the cellular pellet (1.0-1.2 ml) was mixed with an 
equal volume of 2.5% (w/w in PBS) sodium alginate. The mixture 
was manually extruded, under minimal pressure, through a 25-gauge 
needle, on the surface of a 0.1 M CaCl2 solution. The small drops 
(approx. 1 mm diameter) gelled and were immediately washed three 
times in the growth medium. The capsules were isolated by decant-
ation, transferred to a 10 mm screw cap NMR tube, and perfusion 
was promptly initiated. The perfusion solution was IMEM containing 
the 'physiological' concentration of glucose, 4 mM. The perfusion was 
performed through an insert with inlet and outlet tubes, and the 
volume of the perfusion chamber was 2 ml. A constant flow of 0.9 
ml/min in a single pass mode was maintained by a peristaltic pump 
(Pharmacia P-3, Pharmacia LKB Biotechnology Inc.), and the tem-
perature was maintained at 37°C. The effluent was collected for glu-
cose and lactate assays. In each experiment control perfusion with 31P 
NMR recording was carried out for 3 h, to ensure metabolic stability 
of the cells, before adding TNF-a to the perfusion solution. 31P Spec-
tra were recorded on a Varian XL-400 spectrometer at 162 MHz, 
using 3 s relaxation delays, 45° radio-frequency pulses, and 200 tran-
sients in each spectrum. Peak integrals were used for monitoring the 
effects of TNF-a on the spectra. Cellular viability was evaluated by 
the trypan blue dye at the end of each perfusion experiment. 
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2.4. Glucose and lactate determination 
Glucose and lactate concentrations were determined in perchloric 
acid treated samples, immediately following collection. Glucose con-
centrations were measured by the hexokinase enzymatic assay, using 
coupled enzyme reaction catalyzed by hexokinase and glucoses-phos-
phate dehydrogenase, and measuring the product, NADH, at 340 nm. 
Lactate levels were determined utilizing the formation of NADH (and 
pyruvate) from lactate in the presence of hydrazine (to trap formed 
pyruvate) and excess NAD. The reaction is catalyzed by lactate de-
hydrogenase, and the lactate concentrations were calculated from the 
absorbance at 340 nm. Absorbance measurements were performed 
with a Shimadzu UV-160 spectrophotometer (Shimadzu Co.). 
Quantitative results are expressed as means ± S.D. Statistical anal-
yses were performed with the paired, double-tailed, Student's 7-test 
(P<0.05). 
3. Results and discussion 
The effects of TNF-a on the growth of cultured MCF-7 
cells are shown in Fig. 1. A dose dependent inhibition by 
TNF-a was demonstrated, and these effects were rather 
prompt as considerable growth inhibition was observed even 
after an incubation time of 2 days. The effects of TNF-a were 
modified however by glucose concentrations in the medium. 
Fifty percent growth inhibition was obtained after 2 days with 
TNF-a concentrations of » 50, 33 and 22 ng/ml for 25, 11 
and 4 mM glucose, respectively, and 47, 17.5 and 8.5 ng/ml 
for 25, 11 and 4 mM glucose, respectively, after 5 days. The 
differences in the results of the growth inhibition assays be-
tween the various glucose concentrations were statistically sig-
nificant in the two aforementioned time periods (P<0.05). 
Thus, higher glucose levels provided protection against 
TNF-a-induced cytotoxicity. 
The effects of TNF-a on glucose consumption by MCF-7 
cells are shown in Fig. 2. Preliminary experiments showed that 
in the first 2 days after plating, cell numbers were too small to 
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Fig. 1. Effects of TNF-a on the growth of MCF-7 cells cultured at different glucose concentrations. 25 X104 cells were plated in 25-cm2 flasks 
in 10 ml of IMEM (11 mM glucose). Twenty-four hours later, the medium was replaced with new growth medium with various concentrations 
of TNF-a. Surviving cells were counted after 2 (A) or 5 (B) days. The results were standardized to 100% of the control cells (without TNF-a). 
Mean ± S.D. of six measurements are presented. 
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Fig. 2. Effects of TNF-a on glucose consumption by MCF-7 cells. 25 X104 cells were plated in 25-cm2 flasks in 10 ml of IMEM (11 mM glu-
cose), and when they reached 40 ±5% confluency, the medium was changed to IMEM (11 mM glucose) with various TNF-a concentrations. 
After 2 days, samples of medium were taken for glucose measurements, and a cell count (in flasks plated only for this purpose) was performed. 
Twenty-four hours later, medium samples were withdrawn again, and all cells were harvested and counted. Glucose utilization was calculated 
from the decrease in glucose concentrations over a period of 24 h relative to the average number of cells in that period. Mean ± S.D. of six 
measurements are presented. 
detect changes in glucose concentrations accurately; therefore, 
glucose consumption was measured after 2 days. Glucose con-
sumption was calculated from the changes in glucose concen-
trations over a period of 24 h, and is expressed relative to the 
average number of cells in that period. TNF-a markedly in-
creased glucose consumption by MCF-7 cells, and at the con-
centration of 50 ng/ml the cells utilized 120% more glucose 
than untreated cells (P < 0.03). It should be noted that the 
MCF-7 cells were inhibited by TNF-a even in cultures where 
glucose was not completely depleted, and therefore, the tox-
icity of TNF-a cannot be solely attributed to lack of glucose 
and cell starvation. 
31P NMR spectra of perfused MCF-7 cells are shown in 
Fig. 3. Peaks were assigned according to previously reported 
data [12]. Addition of TNF-a (20, 50 and 200 ng/ml) to the 
perfusion solution caused no spectral changes. In this system, 
dead cells result in signal reduction, but even 48 h of perfusion 
with very high concentration of TNF-a (200 ng/ml, Fig. 3B), 
there was neither signal loss nor ATP depletion. It is note-
worthy that in our previous NMR studies when cells were 
treated with metabolic inhibitors or cytotoxic agents ATP 
depleted preceding cell death [12,13]. Moreover, trypan blue 
exclusion dye examinations of the cells at the end of these 
prolonged perfusions demonstrated 90-95% cellular viability. 
The perfusion system was also used for simultaneous NMR 
and glucose consumption and lactate production studies, thus 
correlating the energy status with glucose metabolism under 
physiological conditions. The results of these experiments are 
presented in Table 1. In the control experiments, the cells were 
perfused with IMEM (4 mM glucose), and glucose and lactate 
levels, which were measured in the effluent every 3 h, were 
stable for a perfusion period of 12 h. In the TNF-a experi-
ments, cells were perfused as described before for 3 h, and 
samples were withdrawn for glucose and lactate determina-
tions, followed by the addition of TNF-a (200 ng/ml) to the 
perfusion solution, and glucose and lactate were measured 
after 3 h of perfusion with TNF-a. TNF-a induced significant 
increase in glucose utilization and lactate production 
(P<0.05, for both glucose and lactate). It is noteworthy 
though that the increase in glucose consumption exceeded 
the increase in lactate production. This may indicate that 
TNF-a induced also a change in the energy metabolism to-
wards oxidative respiration, or that the products of glucose 
metabolism were used for the synthesis of protein and DNA. 
The marked increase in glucose consumption (elevation of 
more than 100% compared to control) caused very low glu-
cose levels in the medium. However, there were no deleterious 
effects on the cells under these conditions as observed by the 
NMR spectra and the trypan blue examinations, probably due 
to the continuous supply of glucose and removal of waste 
products. 
The cytotoxic mechanism of TNF-a is very complex and 
may induce both apoptotic and necrotic forms of cell lysis 
[2,14]. Oxygen is required for these processes [15], and it seems 
therefore that oxygen free radicals are involved in this mech-
anism. There is no unambiguous evidence that TNF-a directly 
hinders the synthesis of DNA, RNA or proteins. However, 
Table 1 
Effects of TNF-a on glucose and lactate levels in perfused MCF-7 
cells 
Glucose (mM) Lactate (mM) 
Perfusion solution 
Effluent, control 
Effluent with TNF 
3.96 ±0.05 
2.65±0.16 
1.27±0.13 
1.47±0.12 
2.34 ±0.11 
MCF-7 cells in alginate capsules were perfused with IMEM contain-
ing 4 mM glucose, at a constant rate of 0.9 ml/min, at 37°C. Follow-
ing 3 h of initial perfusion, three samples of each perfusion solution 
and effluent were collected at 30 min intervals, and thereafter, TNF-a 
(200 ng/ml) was added to the perfusion solution. Three hours later, 
effluent samples were similarly collected. The means and S.D.s of 
three different experiments (total of nine measurements) are presented. 
In control experiments, glucose and lactate levels were stable for a 
perfusion period of 12 h. Lactate levels in the perfusion solution were 
negligible. 
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Fig. 3. 31P NMR spectroscopy of perfused MCF-7 cells in alginate 
capsules. For perfusion conditions and acquisition parameters see 
Section 2. Line broadening of 15 Hz was used. Chemical shifts were 
determined by standardizing GPC to 0.49 ppm. PE, phosphoetha-
nolamine; PC, phosphocholine; Pi, inorganic phosphate; GPE, glyc-
erophosphoethanolamine; GPC, glycerophosphocholine; PCr, phos-
phocreatine; NAD, nicotineamid dinucleotide; DPDE, diphos-
phodiester. A, control; B, 48 h after adding TNF-a (200 ng/ml) to 
the perfusion solution (IMEM, 4 niM glucose). 
inhibition of transcription or protein synthesis by metabolic 
inhibitors sensitizes cells to the cytotoxic action of TNF-a 
[4,6,7], suggesting that cells synthesize proteins that protect 
them from TNF-a effects. 
The role of TNF-a in the treatment of cancer patients has 
been assessed in several clinical trials [16,17], but it appears 
that its use is limited because of severe systemic side effects, 
and wide variation in tumor sensitivity. Recently, TNF-a was 
used in isolated limb perfusion for the treatment of soft tissue 
sarcoma and malignant melanoma in combination with hyper-
thermia and conventional chemotherapy [18,19]. In solid tu-
mors TNF-a may exert its effects through damage to the 
endothelium, and intravascular coagulation leading to ische-
mia, and not necessarily by direct toxicity against the tumor 
cells [20]. This mechanism may be particularly relevant to 
isolated limb perfusion therapy, and our finding that TNF-a 
was not toxic to perfused MCF-7 cells supports this hypoth-
esis. 
Persistent TNF-a production may causes cachexia, and it 
has been shown that TNF-a is identical to cachectin, which 
mediates the wasting of chronic infections [21]. The effects of 
TNF-a on energy and glucose metabolism are diverse, and 
were extensively studied in inflammation and septic shock 
models. In these situations TNF-a induces lipolysis, catabo-
lism, and insulin resistance [21-23]. On the other hand, TNF-
a increased glucose transport and utilization in several trans-
formed, as well as normal, cell lines [24-27]. We found that 
TNF-a induced a dose dependent remarkable elevation of 
glucose consumption in MCF-7 human breast cancer cells. 
It is postulated that in cancer patients with very high levels 
of TNF-a, the much augmented glucose requirements are as-
sociated with the altered metabolism and cachexia. 
Our studies demonstrated profound discrepancies between 
results obtained in cultured and perfused cells, and perhaps 
explain the inconsistent data regarding the effects of TNF-a in 
the laboratory and in the clinical setting. In the traditional 
growth inhibition assays cells are incubated for several days 
with a drug, a situation where their metabolism is altered due 
to the depletion of nutrients, the accumulation of toxic waste 
materials and pH changes. Perfusion methods are more rele-
vant to in vivo conditions, and we suggest that this method-
ology should be used more often in experimental studies of 
physiology and metabolism, and in the development of ther-
apeutic modalities. 
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